-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the announcement, on January 31, 2019, the Drug Review Center of the State Drug Administration accepted the application submitted by the company for the registration of Acapo sugar tablets.
suitable for treating type 2 diabetes, as well as for reducing post-meal blood sugar in people with low sugar tolerance.
Acapo sugar tablets, developed by Bayer under the trade name "Glucobay ®", first listed in Germany in 1990 and approved in Japan in 1993, produced by Bayer Pharma AG A capo sugar tablets were first approved for import into China in December 1994, and in September 1999 the State Drug Administration approved the production of Akapo sugar tablets by Bayer Pharmaceutical and Health Care Co., Ltd., with the ®.
At present, there are Hangzhou Sino-American East China Pharmaceutical Co., Ltd. Akapo sugar tablets (50mg, 100mg), Beijing Fuyuan Pharmaceutical Co., Ltd. Akapo sugar tablets (50mg) through the consistent evaluation;
, Sichuan Green Leaf Pharmaceutical Co., Ltd.'s Acapo sugar capsules (50mg) also passed a consistent evaluation.
, Acapo sugar tablets will have global sales of approximately US$65,536.71 million in 2019, including approximately US$56,718.95 million in the domestic market and US$16,647.19 million in the January-March 2020 period, including approximately US$14,543.12 million in the domestic market (data from IMS).
, the company has invested about RMB15.14 million in the research and development of Acapo sugar tablets.
.